StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Retacrit [legacy through FY23] by Quarter

Retacrit (epoetin alfa biosimilar) [legacy through FY23] — U.S. revenues ($M) ($M)

QuarterlyAnnual

Pfizer Retacrit [legacy through FY23]: $58M in Q4 2023, down 10.8% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2023
58
Period ended Dec 31, 2023
Change on a year earlier
-10.8%
65 in Q4 2022
History
21 quarters
Since Q4 2018
Sources
17
Documents cited below

Where the Q4 2023 figure comes from

“|| Retacrit | 79 | 86 | (8%) | (10%) | 58 | 65 | (11%) | 21 | 21 | 1% | (5%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRetacrit (epoetin alfa biosimilar) [legacy through FY23] — U.S. revenues ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202358-10.8%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2023Oct 1, 202361-6.2%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 202368-20.9%Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 202372-24.2%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 202265-31.6%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 202265-24.4%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2022Jul 3, 202286+10.3%Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2022Apr 3, 202295+11.8%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2021Dec 31, 202195+28.4%Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2021Oct 3, 202186+14.7%Form 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2021Jul 4, 202178+23.8%Form 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗
Q1 2021Apr 4, 202185+28.8%Form 8-K (Earnings / Guidance Release) (pfe-04032022xex99.htm, filed 2022-05-03) ↗
Q4 2020Dec 31, 202074+37.0%Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
Q3 2020Sep 27, 202075+78.6%Form 8-K (Earnings / Guidance Release) (pfe-10032021xex99.htm, filed 2021-11-02) ↗
Q2 2020Jun 28, 202063+110.0%Form 8-K (Earnings / Guidance Release) (pfe-07042021xex99.htm, filed 2021-07-28) ↗
Q1 2020Mar 29, 202066+371.4%Form 8-K (Earnings / Guidance Release) (pfe-04042021xex99.htm, filed 2021-05-04) ↗

Breakdown

What makes up retacrit [legacy through FY23]

Cite this data

StockData. (2026). Pfizer Retacrit [legacy through FY23] ($M), quarterly Q4 2018–Q4 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/retacrit-leg-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.